Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SEMA3B
REST API REST API
Homo sapiens
SEMA3B is differentially expressed in 232 experiments: 129 organism parts: liver, placenta, ... (127 more);, 158 disease states: normal, cervical carcinoma, ... (156 more);, 68 cell types 399 cell lines 27 compound treatments and 61 other conditions.
Synonyms LUCA-1, semaV, sema5, SEMAA, SemA
InterPro Term Plexin_repeat, Ig_sub, Plexin-like, Ig-like, Semaphorin/CD100_Ag
Gene Ontology Term endoplasmic reticulum, protein binding, membrane, extracellular region, cell-cell signaling, axon guidance, multicellular organismal development, receptor activity
UniProt Accession Q13214, F5H2H7, B4DEK9, F5H6N7
Search EB-eye ENSG00000012171
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
MCF-7
1
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
DU145
2
E-GEOD-17482, E-GEOD-20089
MDA468
2
E-MEXP-440, E-MTAB-62
393 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, ... (35 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-22373, E-GEOD-3982
neutrophil
2
E-GEOD-12662, E-GEOD-3982
endometrial tissue;vaginal tissue;myometrial tissue
1
E-MEXP-1251
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
trabecular meshwork cell
1
E-GEOD-492
osteoblast
1
E-MEXP-1216
62 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-TABM-15, E-GEOD-12254, E-GEOD-16363, ... (54 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-GEOD-2514, E-MTAB-37, E-MEXP-231, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
adenocarcinoma
2
E-MEXP-1331, E-MTAB-37
colon carcinoma
2
E-MTAB-37, E-MTAB-62
acute promyelocytic leukemia
1
2
E-MTAB-62, E-GEOD-995, E-GEOD-1729
placental choriocarcinoma
1
E-MTAB-62
152 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-6907, E-GEOD-5741, E-GEOD-5824, E-GEOD-6462, ... (17 experiments)

Factor Value U/D Experiments
none
1
3
E-GEOD-412, E-GEOD-5230, E-GEOD-4668, E-GEOD-5824
5-aza-2'-deoxycytidine + trichostatin A
2
E-GEOD-5230, E-MEXP-1269
FCCP
1
E-MEXP-2285
5-aza-2'-deoxycytidine
2
1
E-GEOD-5230
selenium
1
E-MEXP-1327
ethanol
1
E-MEXP-2241
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-3140, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-21138, E-GEOD-3013

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-20847, E-MTAB-108

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-TABM-321, E-GEOD-2724, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446, E-GEOD-22278, E-MEXP-1103, E-GEOD-1692 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-GEOD-1703, E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-7540, E-GEOD-7307

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-15799

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-GEOD-4922

Processing time: 0.387 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM